ARQ-154 Foam 0.3%

· Arcutis Biotherapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARQ-154 Foam 0.3%, covering 2026-01-14 to 2026-01-14. Get the full timeline:

Most recent: Clinical Trial Update: Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis [Phase 1]

See pricing